SCHEMBL1198162

SCHEMBL1198162

COC(=O)c1ccc(C(C)c2nc(-c3cccc(C(F)(F)F)c3)cs2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.54
SIRT5 Q9NXA8 2/20 0.53
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CFTR P13569 2/20 0.51
PTPRB P23467 1/20 0.46
AKR1C3 P42330 2/20 0.44
AKR1C2 P52895 2/20 0.44
SDHB P21912 1/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
MPL P40238 1/20 0.43
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
CSNK2A3 Q8NEV1 1/20 0.42
GCGR P47871 1/20 0.41
GIPR P48546 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12890178 0.90 ADAM17 (0.65) ADAM17SIRT5ALDH1A1KDM4EMEN1
SCHEMBL1199322 0.89 ALDH1A1 (0.66) ADAM17SIRT5ALDH1A1KDM4EMEN1
SCHEMBL12876815 0.85 SIRT5 (0.52) SIRT5ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1198639 0.80 KDM4E (0.47) ADAM17SIRT5ALDH1A1KDM4EMEN1
SCHEMBL1198959 0.80 SIRT5 (0.48) ADAM17SIRT5ALDH1A1KDM4EMEN1
SCHEMBL7215544 0.79 ALDH1A1 (0.67) SIRT5ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1198556 0.79 ALDH1A1 (0.55) SIRT5ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1198972 0.77 ADAM17 (0.70) ADAM17SIRT5ALDH1A1KDM4EMEN1
SCHEMBL12876923 0.75 SIRT5 (0.52) ADAM17SIRT5ALDH1A1KDM4EMEN1
SCHEMBL1197917 0.74 ALDH1A1 (0.52) SIRT5ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
CN-102056907-A Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-05-11 CN disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ADAM17 2972/4885SIRT5 531/4885ALDH1A1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.